MicroSigX Expands into a New Office — Powering the Next Phase of Growth
We are excited to share that MicroSigX has moved into a new office — a milestone that reflects our transition from innovation to acceleration.
While our laboratories continue to drive the “Mind” — pushing the frontier of microbiome science, this new office serves as the powerhouse for our “Market” — strengthening regulatory execution, commercialization, and global expansion.
As we scale, our pipeline continues to advance, including:
- M3CRC (2nd Generation) for colorectal cancer risk prediction,
- MSX Metagenie® for ASD risk prediction,
- Enterosight® (upcoming) targeting IBD,
with additional inventions progressing in parallel.
Together, these innovations reinforce our ambition to translate science into real-world clinical and commercial impact.
Driven by our Mind-to-Market® approach, we are building a scalable platform, from Hong Kong to global markets — a bigger platform, a stronger pipeline, and a clear path to growth. Stay tuned. The next wave of innovation is coming.
MicroSigX — Transform Lives with Microbial Diagnostics
#MicroSigX #MindToMarket #生物科技增長 #診斷技術 #商業化 #微生物組 #精準醫療 #香港創科
